Recursion Pharmaceuticals, Inc. (RXRX)

Market Cap	2.31B
Revenue (ttm)	43.69M
Net Income (ttm)	-715.54M
Shares Out	520.46M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,674,571
Open	4.760
Previous Close	4.680
Day's Range	4.440 - 4.960
52-Week Range	3.790 - 12.360
Beta	0.94
Analysts	Buy
Price Target	8.00 (+80.18%)
Earnings Date	Nov 5, 2025

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to trea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 800
• Stock Exchange: NASDAQ
• Ticker Symbol: RXRX
• Website: https://www.recursion.com

Financial Performance

In 2024, Recursion Pharmaceuticals's revenue was $58.84 million, an increase of 32.00% compared to the previous year's $44.58 million. Losses were -$463.66 million, 41.3% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 80.18% from the latest price.

Price Target

$8.0

(80.18% upside)

Analyst Consensus: Buy